Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8 Week, Double-Blind, Randomized, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren /Amlodipine / HCTZ in Patients With Moderate to Severe Hypertension.

Next Previous
Search
Trial Profile

An 8 Week, Double-Blind, Randomized, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren /Amlodipine / HCTZ in Patients With Moderate to Severe Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary) ; Aliskiren/amlodipine; Aliskiren/hydrochlorothiazide; Amlodipine/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Biomarker; Registrational; Therapeutic Use

    • Most Recent Events

    • 22 Jul 2012 Results published in the Journal of Hypertension.
    • 23 Dec 2010 Based on results from this study, the US FDA has approved Amturnide, a fixed combination of aliskiren/amlodipine/hydrochlorothiazide, for the treatment of hypertension, according to a Novartis media release.
    • 30 Sep 2010 Results from a subset of patients presented at the 23rd Scientific Meeting of the International Society of Hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top